These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36601124)

  • 41. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication.
    Horn LA; Chariou PL; Gameiro SR; Qin H; Iida M; Fousek K; Meyer TJ; Cam M; Flies D; Langermann S; Schlom J; Palena C
    J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
    Kalantari Khandani N; Ghahremanloo A; Hashemy SI
    J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion.
    Lan Y; Moustafa M; Knoll M; Xu C; Furkel J; Lazorchak A; Yeung TL; Hasheminasab SM; Jenkins MH; Meister S; Yu H; Schlegel J; Marelli B; Tang Z; Qin G; Klein C; Qi J; Zhou C; Locke G; Krunic D; Derner MG; Schwager C; Fontana RE; Kriegsmann K; Jiang F; Rein K; Kriegsmann M; Debus J; Lo KM; Abdollahi A
    Cancer Cell; 2021 Oct; 39(10):1388-1403.e10. PubMed ID: 34506739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
    Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
    Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.
    Jiang X; Yi L; Li C; Wang H; Xiong W; Li Y; Zhou Z; Shen J
    ACS Nano; 2024 Jan; 18(4):3331-3348. PubMed ID: 38227812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
    Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
    Torres ETR; Emens LA
    Breast Cancer Res Treat; 2022 Jan; 191(2):291-302. PubMed ID: 34716871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
    de Streel G; Bertrand C; Chalon N; Liénart S; Bricard O; Lecomte S; Devreux J; Gaignage M; De Boeck G; Mariën L; Van De Walle I; van der Woning B; Saunders M; de Haard H; Vermeersch E; Maes W; Deckmyn H; Coulie PG; van Baren N; Lucas S
    Nat Commun; 2020 Sep; 11(1):4545. PubMed ID: 32917858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 60. Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy.
    Mei J; Cai Y; Wang H; Xu R; Zhou J; Lu J; Yang X; Pan J; Liu C; Xu J; Zhu Y
    Clin Immunol; 2023 Jan; 246():109204. PubMed ID: 36503156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.